艾媒咨询 | 2025年中国健康体检行业消费行为调查数据

随着人们健康意识的提升和疾病预防需求的增长，健康体检市场正飞速发展。消费者对健康管理的重视推动了体检市场的细分和升级，同时技术进步也带来了更精准的检测手段和更便捷的服务体验。根据全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2025年中国健康体检行业消费行为调查数据》数据显示，选择两年一次体检的消费者占比最高，达到39.41%，表明超过三分之一的消费者倾向于以两年为周期进行健康管理，反映出他们对定期体检的重视。与此同时，常规体检项目以60.62%的占比位居首位，凸显了大多数消费者对基础健康检查的高度关注。进一步分析发现，生化及实验室检测（包括血常规、尿常规、生化、肝功、肾功、甲功、血糖等）以61.89%的占比成为最受关注的健康指标，体现了消费者对全面、精准的健康数据的需求，也印证了基础检查在健康管理中的核心地位。艾媒咨询分析师认为，未来，随着健康大数据和人工智能的应用，健康体检市场将朝着更精准、更智能、更普惠的方向发展，成为大健康产业的重要组成部分。
With the improvement of people's health awareness and the growth of disease prevention demand, the health examination market is developing rapidly. Consumers' attention to health management has promoted the segmentation and upgrading of the physical examination market, while technological progress has also brought more accurate detection means and more convenient service experience. According to the latest "Survey data of consumption behavior of China's health check-up industry in 2025" released by iiMedia Research, a third-party data mining and analysis institution in the global new economy industry, the proportion of consumers who choose a biennial physical examination is the highest, reaching 39.41%. It shows that more than one-third of consumers tend to conduct health management on a two-year cycle, reflecting the importance they attach to regular physical examinations. At the same time, routine physical examination items ranked first with 60.62%, highlighting the high attention of most consumers to basic health examination. Further analysis found that biochemical and laboratory tests (including blood routine, urine routine, biochemistry, liver function, kidney function, thyroid function, blood sugar, etc.) accounted for 61.89% of the most concerned health indicators, reflecting consumers' demand for comprehensive and accurate health data, and also confirmed the core position of basic examination in health management. Analysts believe that in the future, with the application of health big data and artificial intelligence, the health physical examination market will develop in a more accurate, smarter and more inclusive direction and become an important part of the big health industry.

亿帆医药：2021年第三季度报告

艾媒咨询｜2022-2023年全球与中国大健康产业运行大数据及决策分析报告

随着人们对健康的关注度和需求度的逐渐上升，大健康产业已经成为全球热点和新的经济增长点。大健康产业顺应了中国经济转型升级、绿色发展的趋势，全球医疗健康产业投融资金额最多集中在2021年，全年达到6846.03亿元，投融资数量最多在2019年，达2044起。

艾媒报告 |2019全球及中国大健康产业运行大数据及决策分析报告

本报告研究涉及企业/品牌/案例：恒瑞医药，白云山，111集团，平安好医生，好大夫在线，优健康，春雨医生，微医，丁香医生，和美医疗，北大医疗，PHG,新氧，联合丽格，正广兴家庭医生，强森医疗，微脉，美中嘉和，零氪科技，中有精准医疗，思派网络，普瑞眼科，臻和科技，移宇科技，小鹿医馆，妈咪知道，八百方，京东医药，阿里健康大药房，1药网，一心堂，健一网，好药师，健客网，美丽神器，更美，悦美，美莱整形，伊美尔，丽都整形，芝星整形，欧华美科

大健康产业细分领域的垂直深化，推动了大健康产业格局的不断完善。受政策鼓励和资本推动的影响，2019年，大健康产业在患者服务类领域、医疗服务类领域、医药服务类领域、医疗美容类领域和医疗保健类领域等细分场景快速发展。以恒瑞医药、白云山为代表的传统医药上市公司和以平安好医生、111集团和新氧科技为代表的互联网医疗上市企业各自占据大健康产业领域的一席之地。艾媒商情舆情监测系统数据显示，受2018年和2019年上半年医疗领域负面舆情的影响，大健康产业各上市企业正从低谷平稳回升。艾媒咨询分析师认为，受社会医疗需求和国家政策的推动，大健康产业仍是未来投资的亮点。

The vertical deepening of the large health industry segment has promoted the continuous improvement of the pattern of the big health industry. Influenced by policy encouragement and capital promotion, in 2019, the big health industry developed rapidly in the sub-sectors such as patient service, medical services, medical services, medical and beauty, and health care. The traditional pharmaceutical listed companies represented by Hengrui Medicine and Baiyun Mountain and the Internet medical listed companies represented by Ping An Doctor, 111 Group and New Oxygen Technology each occupy a place in the field of large health industry. According to data from the Aibu Business Intelligence Monitoring System, the listed companies in the big health industry are recovering steadily from the bottom of the market due to the negative public sentiment in the medical field in the first half of 2018 and 2019. Ai Media Consulting analysts believe that the health industry is still the highlight of future investment, driven by social medical needs and national policies.

艾媒咨询|2021全球与中国医药电商市场与发展趋势研究报告

本报告研究涉及企业/品牌/案例：阿里健康，美团，京东健康，叮当快药，1药网，Walgreens，百度健康，药材买卖网，中药材天地网，找药网，九州通，药易购，珍诚医药在线，CVS

在政策利好、互联网技术等多重因素推动下，中国医药电商行业规模持续快速发展，2020年中国医药电商市场交易规模达到1956亿元。当前，中药电商商业模式主要为B2B、B2C、O2O与DTP四种类型，其中，2020年，医药电商B2C模式占比近6%，市场规模为116亿元；医药电商B2C模式占比近84%，市场规模为1640亿元，成为当前的主流。此外，近几年兴起的O2O模式，主要通过“引流-转化-消费-反馈”等实现盈利，而DTP药房模式下，患者在医院开取处方后，药房根据处方以患者或家属指定的时间和地点送药上门，被称为高值新特药直送平台。
Driven by favorable policies, Internet technology and other factors, the scale of China's pharmaceutical e-commerce industry continues to develop rapidly, with the transaction scale of China's pharmaceutical e-commerce market reaching 1956 billion yuan in 2020. At present, the business models of traditional Chinese medicine e-commerce are mainly B2B, B2C, o2o and DTP. In 2020, the B2C model of pharmaceutical e-commerce accounts for nearly 6% and the market scale is 11.6 billion yuan; the B2C model of pharmaceutical e-commerce accounts for nearly 84% and the market scale is 164 billion yuan, which has become the current mainstream. In addition, the o2o mode, which has sprung up in recent years, mainly achieves profits through "drainage transformation consumption feedback". In the DTP pharmacy mode, after patients get prescriptions in the hospital, the pharmacy delivers drugs to the door at the time and place designated by the patients or their families according to the prescriptions, which is known as the high value new special drugs direct delivery platform.

艾媒咨询|2020年中国互联网医疗行业发展专题研究报告

本报告研究涉及企业/品牌/案例：圆心科技集团，圆心医疗科技，圆心惠保，阿里健康，浙一互联网医院，丁香园。

近年来，中国互联网医疗行业发展迅速，从萌芽期步入到高速发展期。2020年，互联网医疗受新冠疫情影响发展继续加快，5G和人工智能技术逐步落地应用也助推行业规模增长。iiMedia Research（艾媒咨询）数据显示，74.4%的受访网民在疫情期间参与过互联网医疗服务，且认为其能够减轻门诊压力和避免交叉感染的网民占比也超过七成。在互联网医疗主要细分市场中，移动医疗平台借助移动互联网普及和物流水平提高，其品牌认知和市场发展较快，2020年中国移动医疗用户规模将达到6.35亿人，市场规模也将超过520亿元。

In recent years, China Internet medical industry has developed rapidly, from the embryonic stage to high-speed development period. In 2020, the development of Internet medical industry will continue to accelerate under the influence of Covid-19, and the application of 5G and AI technology will also boost the growth of the industry scale. As the data of iiMedia Research showed, 74.4% of the interviewed netizens participated in Internet medical services during the Covid-19 period, and more than 70% netizens believed that it could reduce the pressure of outpatient service and avoid cross infection. In the main market segments of Internet medical industry, mobile medical platforms, with the help of the popularization of mobile Internet and improvement of logistics level, have a rapid brand recognition and market development. In 2020, the user scale of China mobile medical industry will reach 635 million, and the market size will also exceed 52 billion yuan.

艾媒咨询|2021全球及中国大健康产业运行大数据及决策分析报告

本报告研究涉及企业/品牌/案例：阿里健康，联合丽格，恒瑞医药，白云山，平安好医生，111集团，新氧，药明巨诺，盘龙药业，先导药业，好大夫在线，优健康，春雨医生，丁香医生，微医

受到人口老龄化、居民患病比例增加等因素影响，国家医疗费用支出不断增加，属于刚性需求；同时，随着人们对健康标准的不断提高以及互联网医疗技术的发展，大健康产业会在相当长的时期内持续保持增长态势。数据显示，2020年中国的大健康产业营收规模超过7万亿元，预计2021年将达8万亿元，增幅达8.1%。其中，得益于大健康产业发展以及疫情期间医药需求增长，生物制药、医疗器械两大细分领域表现良好，成为2020年中国投资热度较高的新经济行业，投资项目金额分别为919亿元和273亿元。
Affected by the aging population and the increasing proportion of residents, the national medical expenditure is increasing, which belongs to the rigid demand; At the same time, with the continuous improvement of people's health standards and the development of internet medical technology, the big health industry will continue to grow for a long time. According to the data, the revenue of China's big health industry will exceed 7 trillion yuan in 2020, and it is expected to reach 8 trillion yuan in 2021, an increase of 8.1%. Among them, thanks to the development of big health industry and the growth of pharmaceutical demand during the epidemic period, biopharmaceuticals and medical devices have performed well, becoming China's new economy industry with high investment enthusiasm in 2020, with investment projects of 91.9 billion yuan and 27.3 billion yuan respectively.

艾媒咨询 | 2025年中国夜间用药市场发展状况与消费者行为调查数据

在消费观念升级与健康意识觉醒的双重驱动下，中国夜间用药市场正迎来结构性变革。根据全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2025年中国夜间用药市场发展状况与消费者行为调查数据》数据显示，2024年人均医疗保健支出为2547元。未来，随着科技进步带来医疗服务与产品的升级，中国人均医疗保健支出有望继续保持增长趋势。在2025年中国夜间用药消费者夜间购药药品种类中，感冒发烧药品占比31.22%，是所有药品中占比最高的。肠胃消化药品夜间购药占比第二，达到25.04%。整体来看，夜间购药以感冒发烧和肠胃消化等常见病症药品为主。在2025年中国夜间用药消费者夜间线上买药原因中，“夜间外出买药不安全”，达到63.51%。其次是“有些药品不好意思直接买/保护购药者隐私”，占比43.24%，说明夜间线上买药的安全性和隐私保护是夜间用药消费者的主要考虑因素。艾媒咨询分析师认为，未来中国夜间用药市场将呈现三大趋势：一是产品向天然成分、低副作用方向迭代，中药夜间用药市场潜力有望进一步释放；二是渠道融合加速，线上线下一体化的 “夜间健康服务圈” 将成为主流；三是智能化服务深化，通过 AI 问诊、智能药盒等技术提升用药安全性与便利性。企业需聚焦细分场景需求，加强产品创新与服务赋能，推动夜间用药市场向规范化、专业化方向发展。
Driven by the dual impetus of the upgrading of consumption concepts and the awakening of health awareness, the night-time medication market in China is undergoing a structural transformation. According to the latest "iiMedia Report | Survey data on the development status and consumer behavior of China's nighttime medication market in 2025" released by iiMedia Research, a leading third-party data mining and analysis institution for the new economy industry worldwide, the per capita healthcare expenditure in 2024 was 2,547 yuan. In the future, with the upgrading of medical services and products brought about by technological progress, China's per capita healthcare expenditure is expected to continue to grow. In 2025, among the types of medicines purchased by Chinese consumers at night, cold and fever medicines accounted for 31.22%, which was the highest proportion among all medicines. The proportion of night-time purchases of gastrointestinal digestion drugs ranked second, reaching 25.04%. Overall, when purchasing medicine at night, the main focus is on common conditions such as colds, fevers, and gastrointestinal disorders. Among the reasons why Chinese consumers purchase medicine online at night in 2025, "It is not safe to buy medicine outside at night" accounted for 63.51%. The second is "Some medicines are too embarrassing to be purchased directly/protecting the privacy of the purchasers", accounting for 43.24%, indicating that the safety and privacy protection of online medicine purchases at night are the main considerations for consumers taking medicine at night. Analysts from iiMedia Research believe that the future night medicine market in China will present three major trends: First, products will evolve towards natural ingredients and low side effects, and the potential of the traditional Chinese medicine night medicine market is expected to be further released; Second, the integration of channels is accelerating, and the "nighttime health service circle" that integrates online and offline will become the mainstream. Third, intelligent services have been deepened, and the safety and convenience of medication have been enhanced through technologies such as AI consultation and smart medicine boxes. Enterprises need to focus on the demands of specific scenarios, enhance product innovation and service empowerment, and promote the development of the night medication market towards standardization and professionalization.

艾媒咨询|2020上半年中国网络互助发展专题研究报告

本报告研究涉及企业/品牌/案例：e互助、相互宝。

在国家政策的支持下，中国网络互助行业不断发展，逐渐成为医疗保障的有益补充。2019年中国网络互助行业救助总人数规模超过3万人，行业救助总金额超50亿元。截至2019年年底，中国网络互助覆盖人数达1.5亿人，预计2020年中国网络互助覆盖率达17.8%，2022年网络互助覆盖人数达有望达到3.9亿，覆盖率将达27.8%。通过网络互助平台的对比，结果显示，相较于报销型和综合型平台，给付型和聚焦型平台在人均互助金、获助比例等方面更具优势，e互助综合能力领先各平台。目前没有发现网络互助行业的规模效应，平台会员分摊未来有望保持平稳发展。未来中国网络互助将进入繁荣发展期，有望成为“国民级”产品，专业化运营与风险管控将成平台重点发展方向，行业也将从同质化到募集效率、金额的差异化发展。

With the support of national policies, China's network mutual assistance industry has continued to develop and has gradually become a useful supplement to medical security. In 2019, the total number of people assisted by China's network mutual assistance industry exceeded 30,000, and the total amount of industry assistance exceeded 5 billion yuan. At the end of 2019, the number of people covered by China's network mutual assistance reached 150 million. It is estimated that the coverage rate of China's network mutual assistance will reach 17.8% in 2020, and the number of network mutual assistance coverage is expected to reach 390 million in 2022, with a coverage rate of 27.8%. Through the comparison of network mutual assistance platforms, the results show that, compared with reimbursement and integrated platforms, payment and focused platforms have more advantages in terms of per capita mutual assistance, the proportion of assistance and so on. Besides, the comprehensive ability of “E HUAZHU” leads all platforms. At present, the scale effect of the network mutual assistance industry has not been found, and the platform members are expected to maintain stable spending in the future. In the future, China's network mutual assistance will enter a period of prosperity and development, and it is expected to become a "national-level" product. Professional operation and risk management will become the key development direction of the platforms. The industry will also develop from homogeneity to differentiated development in raising efficiency and amount.

艾媒咨询|2021年中国医美机构市场竞争态势及企业营销模式分析报告

本报告研究涉及企业/品牌/案例：华韩整形，瑞丽医美，美莱整形，医思健康

数据显示，2016—2020年中国医美行业市场规模五年平均增长率为12.8%，与此同时，中国医美市场用户规模增长了4倍多。在人们生活水平的提升、年轻一代对医美的接受度的提高、政府监管层对医美行业的整治给医美消费者信心的提升的综合作用下，预计中国医美市场规模在2022年将达到2232亿元。随着医美产品及仪器技术水平提升、医美知识普及等，民众对整形美容的观念正在向积极态度转变，在整个行业扩张的过程中，轻医美的受众面广、门槛低、复购率高，更有可能提升市场整体渗透率，成为我国医美行业的主要增量市场。
According to the data, from 2016 to 2020, the five-year average growth rate of the market scale of China's medical and American industry was 12.8%. At the same time, the user scale of China's medical and American market increased by more than four times. Under the combined effect of the improvement of people's living standards, the improvement of the acceptance of medical beauty by the younger generation, the regulation of the medical beauty industry by the government regulators and the improvement of medical beauty consumer confidence, it is expected that the scale of China's medical beauty market will reach 223.2 billion yuan in 2022. With the improvement of the technical level of medical beauty products and instruments and the popularization of medical beauty knowledge, people's concept of plastic beauty is changing to a positive attitude. In the process of the expansion of the whole industry, light medical beauty has a wide audience, low threshold and high repurchase rate, which is more likely to improve the overall penetration rate of the market and become the main incremental market of China's medical beauty industry.